A prospective study on Foxp3+CD25highCD4+ regulatory T cells in chronic hepatitis C infected patients undergoing direct-acting antiviral combination therapy
Ramadan, R., Mohammed, A. (2019). A prospective study on Foxp3+CD25highCD4+ regulatory T cells in chronic hepatitis C infected patients undergoing direct-acting antiviral combination therapy. EKB Journal Management System, 28(2), 105-111. doi: 10.21608/ejmm.2019.282703
Raghdaa A. Ramadan; Ahmed S. Mohammed. "A prospective study on Foxp3+CD25highCD4+ regulatory T cells in chronic hepatitis C infected patients undergoing direct-acting antiviral combination therapy". EKB Journal Management System, 28, 2, 2019, 105-111. doi: 10.21608/ejmm.2019.282703
Ramadan, R., Mohammed, A. (2019). 'A prospective study on Foxp3+CD25highCD4+ regulatory T cells in chronic hepatitis C infected patients undergoing direct-acting antiviral combination therapy', EKB Journal Management System, 28(2), pp. 105-111. doi: 10.21608/ejmm.2019.282703
Ramadan, R., Mohammed, A. A prospective study on Foxp3+CD25highCD4+ regulatory T cells in chronic hepatitis C infected patients undergoing direct-acting antiviral combination therapy. EKB Journal Management System, 2019; 28(2): 105-111. doi: 10.21608/ejmm.2019.282703

A prospective study on Foxp3+CD25highCD4+ regulatory T cells in chronic hepatitis C infected patients undergoing direct-acting antiviral combination therapy

Egyptian Journal of Medical Microbiology
Volume 28, Issue 2, April 2019, Page 105-111  XML PDF (318.2 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2019.282703
View on SCiNiTO View on SCiNiTO
Authors
Raghdaa A. Ramadan email 1; Ahmed S. Mohammed2
1Medical Microbiology and Immunology Department Faculty of Medicine, Zagazig University, Egypt
2Tropical Medicine Department Faculty of Medicine, Zagazig University, Egypt
Abstract
Background: Immunopathology is responsible for clinical sequelae of chronic HCV infection, FoxP3+CD25highCD4+ regulatory T cells (Tregs) are the master regulators of several immune functions and monitoring their dynamics during HCV infection and after viral clearance is of great importance. Objective: to investigate alterations in FoxP3+CD25highCD4+Treg cells frequency and their FoxP3 expression level in chronic HCV infected Egyptian patients undergoing interferon-free direct acting antiviral (DAA) therapy in comparison to healthy controls. Methodology: Twenty chronic HCV patients undergoing sofosbuvir/daclatasvir combination therapy were included, circulating FoxP3+CD25highCD4+ Treg cells frequency and their FoxP3 expression were assessed by flow cytometry before and at 2 time points after completing the treatment course, correlated with clinical and radiological data at enrollment and compared to those of 20 healthy anti-HCV negative blood donors. Results: Circulating FoxP3+CD25highCD4+ Treg cells frequency and their FoxP3 expression were significantly elevated in chronic HCV patients before treatment with no correlation to virus load, ALT level or fibrosis grade. Treg parameters falls significantly after sofosbuvir/daclatasvir therapy. Treg frequency remained significantly higher than controls 6 months after treatment. Conclusion: DAA therapy was effective at reducing Treg cells frequency and FoxP3 expression but the persistent higher level than normal after 6 months of viral eradication should be further investigated to find out when they will normalize and their influence on the future course of the disease.
Keywords
Chronic HCV; Direct-acting antivirals; flow cytometry; Regulatory T cells
Statistics
Article View: 43
PDF Download: 21